Insider Transactions in Q1 2024 at Bristol Myers Squibb CO (BMY)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,323
-26.04%
|
$229,119
$53.79 P/Share
|
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
4,569
-16.83%
|
-
|
|
Mar 10
2024
|
Adam Lenkowsky EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,016
+41.58%
|
-
|
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
16,660
-1.58%
|
$882,980
$53.79 P/Share
|
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
SELL
Other acquisition or disposition
|
Direct |
14,153
-1.29%
|
-
|
|
Mar 10
2024
|
Sandra Leung EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
46,784
+4.01%
|
-
|
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,965
-5.92%
|
$104,145
$53.79 P/Share
|
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Other acquisition or disposition
|
Direct |
2,789
-6.77%
|
-
|
|
Mar 10
2024
|
Robert M Plenge EVP, Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,143
+18.16%
|
-
|
|
Mar 10
2024
|
Ahn Amanda Poole EVP, Chief Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-29.27%
|
$72,875
$53.79 P/Share
|
|
Mar 10
2024
|
Ahn Amanda Poole EVP, Chief Human Resources |
SELL
Other acquisition or disposition
|
Direct |
1,659
-19.04%
|
-
|
|
Mar 10
2024
|
Ahn Amanda Poole EVP, Chief Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
5,458
+45.43%
|
-
|
|
Mar 10
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
13,649
-7.14%
|
$723,397
$53.79 P/Share
|
|
Mar 10
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Other acquisition or disposition
|
Direct |
11,705
-5.19%
|
-
|
|
Mar 10
2024
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
38,388
+14.2%
|
-
|
|
Mar 10
2024
|
Phil M Holzer SVP and Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,389
-3.69%
|
$73,617
$53.79 P/Share
|
|
Mar 10
2024
|
Phil M Holzer SVP and Controller |
SELL
Other acquisition or disposition
|
Direct |
1,682
-3.94%
|
-
|
|
Mar 10
2024
|
Phil M Holzer SVP and Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
5,520
+11.14%
|
-
|
|
Mar 10
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-20.63%
|
$36,888
$53.79 P/Share
|
|
Mar 10
2024
|
Cari Gallman EVP, Corporate Affairs |
SELL
Other acquisition or disposition
|
Direct |
839
-15.09%
|
-
|
|
Mar 10
2024
|
Cari Gallman EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
2,761
+38.11%
|
-
|
|
Mar 10
2024
|
Lynelle Hoch President, Cell Therapy Org. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,308
-35.18%
|
$69,324
$53.79 P/Share
|
|
Mar 10
2024
|
Lynelle Hoch President, Cell Therapy Org. |
SELL
Other acquisition or disposition
|
Direct |
1,317
-19.2%
|
-
|
|
Mar 10
2024
|
Lynelle Hoch President, Cell Therapy Org. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,351
+45.6%
|
-
|
|
Mar 10
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,407
-6.07%
|
$1,028,571
$53.79 P/Share
|
|
Mar 10
2024
|
Christopher S. Boerner Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
16,698
-4.52%
|
-
|
|
Mar 10
2024
|
Christopher S. Boerner Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,638
+12.52%
|
-
|
|
Mar 10
2024
|
Giovanni Caforio Executive Chair of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
67,823
-5.03%
|
$3,594,619
$53.79 P/Share
|
|
Mar 10
2024
|
Giovanni Caforio Executive Chair of the Board |
SELL
Other acquisition or disposition
|
Direct |
57,536
-3.79%
|
-
|
|
Mar 10
2024
|
Giovanni Caforio Executive Chair of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
190,130
+10.83%
|
-
|
|
Mar 10
2024
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,522
-3.11%
|
$981,666
$53.79 P/Share
|
|
Mar 10
2024
|
David V Elkins EVP, Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
19,448
-2.98%
|
-
|
|
Mar 10
2024
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
64,326
+8.75%
|
-
|
|
Feb 01
2024
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
754
-12.48%
|
$36,192
$48.67 P/Share
|
|
Feb 01
2024
|
Gregory Scott Meyers EVP, Chief Digital & Tech Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
2,543
+29.63%
|
-
|